Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial
| Autor: | Mark Trentalange, George M. Anderson, Peter H. Van Ness, Allison F. Wagner, Nicole M. Barcelos, Keith A. Hawkins, Amy F.T. Arnsten, Adam P. Mecca, Mary Sano, Martha G. MacAvoy, Christopher H. van Dyck |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Aging medicine.medical_specialty Prefrontal Cortex Neuropsychological Tests Placebo Article law.invention 03 medical and health sciences 0302 clinical medicine Double-Blind Method Randomized controlled trial Quality of life law Internal medicine Adrenergic alpha-2 Receptor Agonists medicine Humans Cognitive Dysfunction Adverse effect Prefrontal cortex Aged Aged 80 and over business.industry General Neuroscience Age Factors Cognition Confidence interval Guanfacine Treatment Outcome 030104 developmental biology Quality of Life Female Neurology (clinical) Geriatrics and Gerontology business 030217 neurology & neurosurgery Developmental Biology medicine.drug |
| Zdroj: | Neurobiology of Aging. 70:117-124 |
| ISSN: | 0197-4580 |
| DOI: | 10.1016/j.neurobiolaging.2018.05.033 |
| Popis: | This study evaluated the effect of the alpha-2A-adrenoceptor agonist guanfacine on prefrontally mediated cognitive functions, as well as quality of life and global function in healthy older participants. One hundred twenty-three participants aged 75 years and older were randomly assigned to guanfacine 0.5 mg, 0.1 mg, or placebo daily for 12 weeks. The primary outcome measure was the change in z-score for 6 prefrontal executive function tasks over 12 weeks (PEF6). Neither dose of guanfacine improved PEF6 z-score relative to placebo. The rate of mean change (95% confidence interval) in PEF6 z-score over 12 weeks was 0.270 (0.159, 0.380) for placebo, compared with 0.121 (0.011, 0.232) for guanfacine 0.1 mg (p = 0.06, compared to placebo) and 0.213 (0.101, 0.324) for 0.5 mg (p = 0.47). Neither dose of guanfacine improved the quality of life or global function relative to placebo. Among common adverse events, only dry mouth was significantly more frequent on guanfacine compared to placebo. Guanfacine failed to ameliorate prefrontal cognitive function in older individuals, who were cognitively normal for age. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect